



## COI Disclosure

## CCS Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations

Member	Consulting fees/ Honoraria	Speaker's bureau	Equity interests/ Stock options	Equity interests	Royalty income	Non-royalty payments	Officer, director, or in any other fiduciary role	Ownership/ partnership/ principal	Research grants	Fellowship support	Salary	Intellectual property rights	Other financial benefit
André Carpentier	AstraZeneca, GlaxoSmithKline, Merck Frosst, Pfizer and Schering-Plough	None	None	None	None	None	None	None	Aventis, AstraZeneca, GlaxoSmithKline, Merck-Frosst- Schering Plough, Novartis, Pfizer, Philips, and Amsterdam Molecular Therapeutics	None	None	None	None
Patrick Couture	AstraZeneca, Merck Frosst, Merck-Schering, Pfizer and Solvay	None	None	None	None	None	None	None	Merck Frosst, Merck-Schering and Pfizer	None	None	None	None
Robert Dufour	AstraZeneca, Bristol-Merys Squibb, Pfizer, Genzyme, Isis, and/or Merck Frosst	None	None	None	None	None	None	None	AstraZeneca, Bristol-Merys Squibb, Pfizer, Genzyme, Isis, and/or Merck Frosst	None	None	None	None
George Fodor													
Gordon A Francis	AstraZeneca, Merck Frosst, Merck Frosst- Schering, Oryx, and Solvay Pharma	None	None	None	None	None	None	None	an unrestricted research grant from Pfizer Canada	None	None	None	None
Steven Grover													
Milan Gupta	AstraZeneca, Pfizer, Bristol-Myers Squibb, Novartis, Merck Frosst, Oryx, Solvay, Schering-Plough, Abbott	None	None	None	None	None	None	None	AstraZeneca, Pfizer, Merck Schering	None	None	None	None



## COI Disclosure

CCS Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations

Member	Consulting fees/ Honoraria	Speaker's bureau	Equity interests/ Stock options	Equity interests	Royalty income	Non-royalty payments	Officer, director, or in any other fiduciary role	Ownership/ partnership/ principal	Research grants	Fellowship support	Salary	Intellectual property rights	Other financial benefit
Glen J Pearson	Astellas, AstraZeneca, Merck Frosst, Pfizer, Novartis, Roche, Sanofi-aventis and Schering-Plough	None	None	None	None	None	None	None	Fujisawa, Merck Frosst, and Novartis	None	None	None	None
Allan Sniderman	Merck-Schering	None	None	None	None	None	None	None	AstraZeneca	None	None	None	None
James A Stone	AstraZeneca, Bristol-Myers Squibb, Merck Frosst, Novartis, Pfizer, Sanofi-aventis, Servier, and Schering-Plough	None	None	None	None	None	None	None	None	None	None	None	None
Ehud Ur	Merck Frosst, AstraZeneca, Schering-Plough, and/or Pfizer	None	None	None	None	None	None	None	Merck Frosst, AstraZeneca, Schering-Plough, and/or Pfizer	None	None	None	None

## Categories and Descriptions

Consulting fees/Honoraria	including honoraria from a third party, gifts or other consideration, or "in kind" compensation, whether for consulting, lecturing, travel, service on an advisory board, legal testimony or consultation, or for any other similar purpose in the prior calendar year.
Speaker's bureau	
Equity interests/Stock options	(or entitlement to the same), including a non-publicly traded and financially related company.
Equity interests	(or entitlement to the same) in a publicly traded and financially related company
Royalty income	or the right to receive future royalties under a license or copyright, where the topic is directly related to the licensed technology or work under discussion
Non-royalty payments	or entitlements to payments in connection with the activity that are not directly related to the reasonable costs of that activity
Officer, director, or in any other fiduciary role	whether or not remuneration is received for service.
Ownership/partnership/principal	excluding mutual diversified funds
Research grants	from a financially interested company.
Fellowship support	
Salary	Funding of a salary or position (partial or full) or "in-kind" support of program
Intellectual property rights	includes patent or other intellectual property in a for-profit corporation.
Other financial benefit	